Pancreatic enzyme replacement therapy (PERT) is a game-changer in the world of managing digestive disorders like exocrine pancreatic insufficiency (EPI) and cystic fibrosis. In this article, discover the key differences between two commonly prescribed PERT medications: Pancreaze and Creon. Get ready to make informed decisions and empower both patients and healthcare professionals in choosing the perfect treatment option for optimal health!
Active Ingredients
Both Pancreaze and Creon contain a mixture of lipases, proteases, and amylases derived from pig pancreas. However, the exact composition and proportions of these active ingredients may differ between the two medications.
The active ingredient in Pancreaze is pancrelipase. Pancrelipase is a mixture of digestive enzymes including lipases, proteases, and amylases derived from pig pancreas.
On the other hand, the active ingredients in Creon are also derived from pig pancreas and include lipases, proteases, and amylases. However, the specific composition and proportions of these active ingredients may vary depending on the strength of the Creon medication prescribed.
-
Creon$84.37 – $144.41
Enzyme Strengths
Another crucial factor to consider is the enzyme strength available in each medication. Pancreaze comes in various strengths to accommodate individual patient needs, with doses ranging from 5000 to 42000 USP lipase units per capsule. Creon, similarly, offers a wide range of strengths from 3000 to 36000 USP lipase units per capsule. The appropriate strength is determined by the severity of the patient’s condition and their response to treatment.
Administration
Whether swallowed whole or sprinkled on soft acidic food like applesauce, both Pancreaze and Creon offer flexible options for patients who might face challenges swallowing. However, it is essential to follow the specific administration instructions provided by the prescribing healthcare professional.
FDA Approval
Pancreaze and Creon have undergone separate clinical trials for FDA approval. Pancreaze received FDA approval in 2010, while Creon received approval earlier in 2009. Both medications have demonstrated efficacy and safety in treating EPI and other related conditions.
Manufacturer
Pancreaze is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, which is a well-known pharmaceutical company with a strong presence in the healthcare industry. Creon, on the other hand, is manufactured by AbbVie, another reputable pharmaceutical company with a focus on developing innovative therapies.
Availability and Cost
It is essential to note that prices of both Pancreaze and Creon can vary depending on pharmacy location, insurance coverage, and any available discounts or patient assistance programs. The following information is a general overview:
The cost of Pancreaze can vary. On an average, the price for 2600 Pancreaze units (100 capsules) can range from approximately $82 to $90 at different pharmacies in the United States.
On the other hand, the cost of Creon tends to be higher. On an average, Creon (6000 units-19,000 units-30,000 units) can be around $218 for a supply of 100 capsules. Online Canadian Pharmacies like Border Free Health can offer it in a price range of $84.37 – $144.41 for 100 capsules.
It is important to consult with a healthcare professional and check with your specific insurance provider or pharmacy for the most accurate and up-to-date pricing information.
As for availability, both Pancreaze and Creon are prescription-only medications. They are typically available at pharmacies in the United States with a valid prescription from a healthcare provider.